EP3397269A4 - Formulations stables de peptide de glucagon - Google Patents

Formulations stables de peptide de glucagon Download PDF

Info

Publication number
EP3397269A4
EP3397269A4 EP16863067.1A EP16863067A EP3397269A4 EP 3397269 A4 EP3397269 A4 EP 3397269A4 EP 16863067 A EP16863067 A EP 16863067A EP 3397269 A4 EP3397269 A4 EP 3397269A4
Authority
EP
European Patent Office
Prior art keywords
glucagon peptide
stable formulations
formulations
stable
glucagon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16863067.1A
Other languages
German (de)
English (en)
Other versions
EP3397269A1 (fr
Inventor
Mahmoud Ameri
Peter E. Daddona
Yi Ao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gylden Usa Corp
Original Assignee
Zp Opco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/930,041 external-priority patent/US9782344B2/en
Application filed by Zp Opco Inc filed Critical Zp Opco Inc
Publication of EP3397269A1 publication Critical patent/EP3397269A1/fr
Publication of EP3397269A4 publication Critical patent/EP3397269A4/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0046Solid microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0061Methods for using microneedles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP16863067.1A 2015-11-02 2016-11-04 Formulations stables de peptide de glucagon Pending EP3397269A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/930,041 US9782344B2 (en) 2013-08-22 2015-11-02 Stable glucagon peptide formulations
PCT/US2016/060601 WO2017079611A1 (fr) 2015-11-02 2016-11-04 Formulations stables de peptide de glucagon

Publications (2)

Publication Number Publication Date
EP3397269A1 EP3397269A1 (fr) 2018-11-07
EP3397269A4 true EP3397269A4 (fr) 2019-09-04

Family

ID=58662794

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16863067.1A Pending EP3397269A4 (fr) 2015-11-02 2016-11-04 Formulations stables de peptide de glucagon

Country Status (2)

Country Link
EP (1) EP3397269A4 (fr)
WO (1) WO2017079611A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3416618A1 (fr) 2016-02-19 2018-12-26 ZP Opco, Inc. Procédé pour obtenir rapidement des concentrations thérapeutiques de triptans pour le traitement de migraines
US11660264B2 (en) 2017-08-23 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches
US11660265B2 (en) 2018-06-28 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09241295A (ja) * 1996-03-06 1997-09-16 Shiseido Co Ltd 皮膚外用剤
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029364A1 (fr) 1997-12-11 1999-06-17 Alza Corporation Dispositif renforçant le flux d'agents transdermiques
WO2002030300A2 (fr) 2000-10-13 2002-04-18 Alza Corporation Logement pour element a microprotrusions pour applicateur a percussion
EP1333880B1 (fr) 2000-10-26 2009-04-15 Alza Corporation Dispositifs d'administration de medicament transdermique avec des microprotrusions enrobees
WO2002074173A1 (fr) 2001-03-16 2002-09-26 Alza Corporation Procede et appareil de revetement de microprojections de perçage de peau
US8975227B2 (en) * 2005-07-15 2015-03-10 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
US9234023B2 (en) * 2010-06-24 2016-01-12 Biousian Biosystems, Inc. Glucagon-like peptide-1 glycopeptides
WO2015027173A1 (fr) * 2013-08-22 2015-02-26 Zp Opco, Inc. Formules stables de peptides glucagon
US9782344B2 (en) * 2013-08-22 2017-10-10 Zp Opco, Inc. Stable glucagon peptide formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09241295A (ja) * 1996-03-06 1997-09-16 Shiseido Co Ltd 皮膚外用剤
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017079611A1 *

Also Published As

Publication number Publication date
EP3397269A1 (fr) 2018-11-07
WO2017079611A1 (fr) 2017-05-11

Similar Documents

Publication Publication Date Title
IL268697A (en) Formulations
DK3688162T3 (da) Formuleringer
IL257279A (en) Stable anti-ifnar1 formulation
EP3478249A4 (fr) Compositions de microcapsules stables
SI4070787T1 (sl) Farmacevtske formulacije
EP3509581A4 (fr) Formulations de (r
HUE047477T2 (hu) Palbociclib szilárd dózisformái
MA50657A (fr) Formulations de niraparib
EP3407855A4 (fr) Compositions antioxydantes stables
LT3298027T (lt) Antihelmintiniai depsipeptido junginiai
PL3310340T3 (pl) Formulacje o wysokim stężeniu
EP3462885A4 (fr) Formulations de cannabinoïdes stables
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
EP3364945C0 (fr) Formulation solide
EP3368012A4 (fr) Formulations de lisinopril
EP3603642A4 (fr) Préparation pharmaceutique
PL3541200T3 (pl) Formulacje proszkowe
PT3200772T (pt) Composições farmacêuticas compreendendo alpelisib
EP3600279A4 (fr) Formulations d'acide 1-amino-1-cyclopropanecaboxylique
EP3454847A4 (fr) Formulations de médicaments améliorées
EP3704233A4 (fr) Formulations stables de cytomegalovirus
DK3280447T3 (da) Farmaceutiske formuleringer
HUE063178T2 (hu) Kopanlizib formulációi
DK3316856T3 (da) Blandede formuleringer
DK3310331T3 (da) Injicerbare farmaceutiske formuleringer af lefamulin

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180601

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190807

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/19 20060101ALI20190801BHEP

Ipc: A61M 37/00 20060101ALI20190801BHEP

Ipc: A61K 47/26 20060101ALI20190801BHEP

Ipc: A61K 47/12 20060101ALI20190801BHEP

Ipc: A61K 38/26 20060101AFI20190801BHEP

Ipc: A61K 47/24 20060101ALI20190801BHEP

Ipc: A61K 47/18 20170101ALI20190801BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221212

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EMERGEX USA CORPORATION

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GYLDEN USA CORPORATION